Acromegaly or Growth Hormone Excess
Application Due Date: May 28, 2020  - deadline extended to July 15, 2020.
RFP  https://pfe-pfizercom-prod.s3.amazonaws.com/GMG_2020RD9_2020US.pdf

Specific Area of Interest: Research projects that will be considered for Pfizer support will advance the medical knowledge of acromegaly disease, its complications and treatment with pegvisomant. Projects submitted may include:

• Morbidity and mortality in patients with Acromegaly/GH Excess
• Laboratory investigations on effects of pegvisomant
• Clinical outcomes, quality of life, and patient reported outcomes associated with monotherapy or combination therapy including pegvisomant
• Pharmacoeconomics such as but not limited to resource utilization; patient-reported outcomes; treatment patterns

Growth Hormone Research Competitive Grant Program
Application Due Date: May 28, 2020
RFP  https://pfe-pfizercom-prod.s3.amazonaws.com/GMG_2020RD8_2020US.pdf

Specific Area of Interest: Research projects that will be considered for Pfizer support will advance the medical knowledge of short stature.  Projects submitted may include:

• Diagnostics, early treatment of GHD, new treatment paradigms
• Clinical outcomes, quality of life, and patient reported outcomes
• Pharmacoeconomics & medication adherence research 
• Translational or clinical research